TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

TG Therapeutics guided to 2026 U.S. BRIUMVI revenue of $885 million to $900 million and said it is about 3.5 years into the launch. Management highlighted positive ENHANCE study results that could support a 2027 label change to simplify onboarding, plus encouraging subcutaneous program data that may create a new product line. The tone was constructive, with the call emphasizing continued commercial execution and pipeline expansion.

Analysis

The setup is shifting from a pure commercial launch story to a two-step lifecycle extension: label simplification first, then a new route-of-administration opportunity later. That matters because once the current IV franchise is normalized, the market tends to stop paying for “launch optionality” and starts underwriting durability; any evidence that onboarding friction can be removed should improve persistence, prescriber willingness, and center throughput, which is a quiet but meaningful driver of share gains over the next 12-18 months.

The more interesting second-order effect is competitive rather than product-specific. If the onboarding regimen becomes simpler, the real pressure falls on older infused MS therapies whose adoption is already constrained by site logistics and physician time, not just clinical differentiation. A lower-friction regimen also raises the bar for any emerging alternatives, because it makes the incumbent harder to displace without a clearly better convenience profile.

The subcutaneous program is the key longer-dated catalyst, but it also creates a sequencing risk: investors may over-assign value to the platform before regulatory and commercial proof exists. The market could bid the stock on pipeline headlines into the next several quarters, but if the label change slips or uptake in the current franchise decelerates while waiting for the next product line, that narrative can unwind quickly. The critical question is whether management can keep revenue growth compounding through the transition window without forcing a valuation reset.

Contrarianly, the stock may still be underappreciating how much of the upside is operational versus scientific. In a concentrated MS market, small execution improvements can translate into outsized share gains because prescribers are sticky and access improvements compound over time. The risk is that consensus extrapolates too far into the subcu story and ignores that the near-term P&L still depends on maintaining momentum in the existing launch base.

Key Decisions for Investors

• Stay long TGTX into the next 1-3 quarters on the thesis that execution + label simplification should re-rate the durability of the base franchise; target a 15-20% upside window if revenue traction remains intact.
• Add on pullbacks rather than strength: buy TGTX on any 5-8% post-event/market-volatility retracement, with a stop if commercial growth visibly slows for two consecutive prints.
• Pair trade: long TGTX / short a basket of mature infused MS competitors over the next 6-12 months to express a convenience-driven share-gain thesis while hedging broader biotech beta.
• Buy TGTX call spreads dated 6-12 months out to capture the label-change and pipeline catalyst path with defined downside; structure for a 2:1 or better payoff if the market starts capitalizing the subcu opportunity earlier than expected.
• If the stock rallies sharply on subcu headlines before regulatory visibility improves, trim 25-30% into strength and hold the remainder for the operational compounding story rather than paying full price for unproven pipeline optionality.